Selective OX1R Antagonists for Impulse Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dual orexin receptor antagonists are not suitable for treating impulse control deficits in disorders such as addictions, personality disorders, and eating disorders due to their sleep-inducing effects, necessitating the development of selective orexin receptor type 1 (OX1R) antagonists.
Innovation Solution
Development of novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)-propanyl]arylcarboxamide derivatives that act as potent and selective OX1R antagonists, characterized by high potency, selectivity over OX2R, low MDCK efflux, and appropriate log P values, making them suitable for PET radiolabelling and therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual orexin receptor antagonists (OX1R and OX2R) are used, then sleep-inducing effects are achieved, but impulse control deficits cannot be treated
Solution Approach 1:
The patent segments the orexin receptor antagonism function by developing compounds that selectively target only OX1R while excluding OX2R. This is achieved through specific molecular结构设计 that confers selectivity, allowing the same therapeutic platform to be adapted for different indications by controlling receptor selectivity.
2Adaptability or versatility
If OX1R selective antagonists are developed, then impulse control deficits can be treated, but sleep-inducing effects are lost
Solution Approach 1:
The patent applies local quality by creating compounds with specific molecular characteristics that confer OX1R selectivity. The chemical structure includes specific functional groups and spatial arrangements (such as the N-[(pyrimidinylamino)propanyl] and N-[(pyridinylamino)propanyl] moieties) that interact preferentially with OX1R binding sites, enabling indication-specific therapy.
3Measurement precision
If PET ligands are developed for OX1R, then receptor occupancy can be measured, but compound development complexity increases
Solution Approach 1:
The patent achieves universality by designing OX1R antagonists with dual functionality: therapeutic activity for impulse control disorders and suitability as PET radioligands. The compounds possess appropriate physicochemical properties (log P, molecular weight, metabolic stability) that enable both pharmacological action and imaging applications, reducing the need for separate drug and tracer development programs.
Data Source
AI summary
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.